Affitech and Peregrine to collaborate on developing fully human vascular targeting agent antibodies
US biopharmaceutical company Peregrine Pharmaceuticals and antibody therapeutics company Affitech, of Oslo in Norway, are to collaborate on the production of human antibodies for Peregrine's Vascular Targeting Agent (VTA) and anti-angiogenesis programmes.
US biopharmaceutical company Peregrine Pharmaceuticals and antibody therapeutics company Affitech, of Oslo in Norway, are to collaborate on the production of human antibodies for Peregrine's Vascular Targeting Agent (VTA) and anti-angiogenesis programmes.
Peregrine will provide targets and Affitech will apply its human antibody libraries and its proprietary discovery and screening technologies, including its unique AffiScreen platform to generate a panel of fully human antibodies against the targets. The agreement allows flexibility for the development of any clinical candidates that are generated, including joint development, internal development at Peregrine or Affitech, or out-licensing to a third party.
'Our mutual goal is that through this collaboration we will be able to identify a number of fully human monoclonal antibodies that can be used either for our VTA or antiangiogenesis technology platforms,' said Steven King, Peregrine's president and ceo. 'Along with clinical candidates that we have already identified and other collaborations that are underway, we believe we will be able to have several VTAs in the clinic with unique target and effector functions.'